BCC 2023 | Frontline endocrine therapies and ribociclib in early stage HR+ HER2- breast cancer

Eva Ciruelos, MD, PhD, Hospital 12 de Octubre, Madrid, Spain, discusses the use of frontline CDK4/6 inhibitors in combination with endocrine therapy for the treatment of early-stage HR+/HER2- breast cancer. Dr Ciruelos highlights results from the RIGHT Choice trial which suggests that first-line ribociclib plus endocrine therapy can be an efficacious treatment for patients with aggressive, advanced breast cancer. This interview took place at the St. Gallen International Breast Cancer Consensus Meeting in Vienna, Austria.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.